Core Viewpoint - Aipeng Medical's subsidiary Shenzhen Pengrui Brain Science Technology Co., Ltd. has obtained the Medical Device Registration Certificate from the Guangdong Provincial Drug Administration for its portable EEG machine and portable EEG collector, which are key components of the company's multimodal ADHD behavior training system [1] Group 1 - The products, named UMind Pro and UMind SE, are primarily used for the detection, display, storage, and transmission of brain electrical signals [1] - The innovation provides a clinical application pathway for intelligent behavior therapy management of ADHD (Attention Deficit Hyperactivity Disorder) [1] - This milestone is crucial for the implementation of the company's multimodal ADHD behavior training system in practical scenarios [1]

Group 1 - Aipeng Medical's subsidiary, Shenzhen Pengrui Brain Science Technology Co., Ltd., has recently obtained the Medical Device Registration Certificate from the Guangdong Provincial Drug Administration for products including "portable electroencephalogram machines" [1] - For the first half of 2025, Aipeng Medical's revenue composition is entirely from the medical device industry, with a 100.0% share [2] - As of the latest report, Aipeng Medical has a market capitalization of 4.2 billion yuan [3]

智通财经APP讯，爱朋医疗(300753.SZ)公告，公司控股子公司深圳朋睿脑科学技术有限公司于近日取得 广东省药品监督管理局颁发的《医疗器械注册证》，产品名称为：便携式脑电图机、便携式脑电采集 器。 ...

格隆汇9月5日丨爱朋医疗(300753.SZ)公布，公司的控股子公司深圳朋睿脑科学技术有限公司于近日取 得广东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，分别为便携式脑电图机、便携式 脑电采集器。 ...

Core Viewpoint - The announcement highlights that the company's subsidiary, Shenzhen Pengrui Brain Science Technology Co., Ltd., has obtained medical device registration certificates for portable EEG machines and portable EEG collectors, which are essential components of the company's multimodal ADHD behavior training system [1] Group 1 - The registered products include a portable EEG machine and a portable EEG collector, both with a validity period of 5 years [1] - The registration certificate numbers are 粤械注准20252071190 for the portable EEG machine and 粤械注准20252071188 for the portable EEG collector [1] - The development of these products is expected to positively impact the company's expansion in brain science, neurological disease diagnosis, and cognitive training fields [1]

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-050 关于控股子公司获得医疗器械注册证的公告 江苏爱朋医疗科技股份有限公司 产品名称 注册证编号 注册证有效期 注册分类 适用范围 便携式脑电 图机 粤械注准 20252071190 2025年9月1日至 2030年8月31日 第二类 用于成人和6岁以上儿童 的脑电生理信号的检测、 显示、存储和传输。 便携式脑电 采集器 粤械注准 20252071188 2025年8月29日至 2030年8月28日 第二类 用于成人和6岁以上儿童 的脑电生理信号的检测、 显示、存储和传输。 一、医疗器械注册证的主要情况 上述产品实际销售情况取决于未来市场推广效果，公司目前尚无法预测其对公司 未来业绩的影响，敬请投资者注意投资风险。 四、备查文件 1、《中华人民共和国医疗器械注册证》。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）的控股子公司深圳朋睿脑 科学技术有限公司于近日取得广东省药品监督管理局颁发的《中华人民共和国医疗器 械注册证》，具体情况如下： 二、对 ...

Group 1 - Brain-computer interface concept stocks experienced a decline at the beginning of trading on September 5, with Innovation Medical hitting the daily limit down [1] - Rock Mountain Technology fell over 7%, while other companies such as Aipeng Medical, Sanbo Brain Science, and Jihua Group also saw significant drops [1]

Company Overview - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, specializes in the development, production, and sales of medical devices in pain management and nasal care [1][2] - The company's revenue composition includes 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [1] Stock Performance - As of August 29, Aipeng Medical's stock price increased by 2.15% to 33.80 CNY per share, with a total market capitalization of 4.26 billion CNY [1] - Year-to-date, the stock has risen by 92.43%, with a recent decline of 0.76% over the last five trading days, a 9.88% increase over the last 20 days, and a 27.31% increase over the last 60 days [1] Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 159 million CNY, a year-on-year decrease of 11.31%, and a net profit attributable to shareholders of -19.38 million CNY, a decrease of 317.90% [2] - The company has distributed a total of 113 million CNY in dividends since its A-share listing, with 16.36 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Aipeng Medical had 32,400 shareholders, an increase of 57.18% from the previous period, with an average of 2,711 circulating shares per shareholder, a decrease of 36.33% [2] - Notably, the fund "Huaxia Innovation Future Mixed (LOF)" has exited the list of the top ten circulating shareholders [3]

财报体检工具显示： 建议关注公司现金流状况（近3年经营性现金流均值/流动负债仅为-10.3%） 据证券之星公开数据整理，近期爱朋医疗（300753）发布2025年中报。截至本报告期末，公司营业总收 入1.59亿元，同比下降11.31%，归母净利润-1937.91万元，同比下降317.9%。按单季度数据看，第二季 度营业总收入9434.48万元，同比上升2.87%，第二季度归母净利润-172.99万元，同比下降122.95%。本 报告期爱朋医疗公司应收账款体量较大，当期应收账款占最新年报归母净利润比达1470.93%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率63.22%，同比减7.29%，净利 率-12.47%，同比减354.45%，销售费用、管理费用、财务费用总计1.04亿元，三费占营收比65.17%，同 比增15.43%，每股净资产5.33元，同比减3.56%，每股经营性现金流-0.38元，同比减2327.08%，每股收 益-0.15元，同比减317.71% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入 ...

Core Viewpoint - Aipeng Medical (300753.SZ) reported a decline in revenue and a net loss for the first half of 2025, indicating financial challenges for the company [1] Financial Performance - The company achieved operating revenue of 159 million yuan, a year-on-year decrease of 11.31% [1] - The net profit attributable to shareholders of the listed company was -19.38 million yuan, marking a shift from profit to loss compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -20.14 million yuan [1] - Basic earnings per share were -0.1537 yuan [1]